Trials / Terminated
TerminatedNCT02819921
Desvenlafaxine for Treatment of Hot Flashes in Women With Breast Cancer Taking Tamoxifen
Desvenlafaxine for the Treatment of Hot Flashes in Women With Breast Cancer Taking Tamoxifen: a Randomized, Double-blind, Placebo-controlled Study
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 59 (actual)
- Sponsor
- Seoul National University Hospital · Academic / Other
- Sex
- Female
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
This study is a randomized, placebo-controlled study of desvenlafaxine versus placebo. The purpose of this study is to determine if desvenlafaxine was effective in decreasing the frequency and severity of hot flashes in breast cancer patients taking tamoxifen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Desvenlafaxine succinate 100mg | Pristiq 100mg |
| DRUG | Desvenlafaxine succinate 50mg | Pristiq 50mg |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2017-11-10
- Primary completion
- 2019-03-15
- Completion
- 2019-06-15
- First posted
- 2016-06-30
- Last updated
- 2019-09-20
Locations
3 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02819921. Inclusion in this directory is not an endorsement.